Last week, Aurora Cannabis (ACB) became the first cannabis stock to issue sales guidance in a postlegalization environment. Unfortunately, the company’s preliminary fiscal …

What a wild ride it’s been for Kitov Pharma (KTOV). After skyrocketing nearly 170% in Tuesday’s trading session, shares of the pharmaceutical firm …

Tilray (TLRY) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 22% upturn. Why …

Shares of Amarin (AMRN), an Irish biopharma that markets a prescription fish oil medication called Vascepa, are on the move following the company’s …

Catalyst Pharmaceuticals (CPRX) hosted a conference call yesterday to discuss its commercialization plan for the company’s newly FDA-approved LEMS drug, Firdapse. Catalyst announced …

Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) …

Black Friday is past. So is Cyber Monday.

Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …

Today, the FDA approved Theravance’s (TBPH) Yupelri (revefenacin) inhalation solution for the treatment of COPD. Thervance and Mylan (MYL) are partnered on the opportunity.

Did an iceberg just wallop into Omeros (OMER) stock? The drug maker’s shares are plunging at breakneck speed of almost 20%.